Sanofi is to buy Principia Biopharma for up to $3.68 billion ... give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty ...

Liver injuries also prompted the FDA to impose a partial clinical hold on Sanofi's BTK inhibitor tolebrutinib (SAR442168 ... of its $3.7 billion buyout of Principia Biopharma.

The former Missouri quarterback was named the head coach of Principia on April 17. The Panthers were 1-9 in 2024. “I am incredibly honored to join the Principia community,” Mauk said.

This is a phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS). SAR442168 (tolebrutinib) is ...

If you currently subscribe the Kenton Times in print, then your access to the online content is INCLUDED in your subscription! Just verify your subscription to get started!